dextrothyroxine has been researched along with Cancer of Prostate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, M; Lv, S; Pascal, LE; Wang, Z; Wei, Q; Wu, Z; Zhang, J; Zhang, Y | 1 |
| Hussein, MA; Munirathinam, G; Samy, A | 1 |
| Bakthavachalam, V; Chinnapaka, S; Munirathinam, G; Samy, ALPA; Vinjamuri, S; Vudutha, M | 1 |
3 other study(ies) available for dextrothyroxine and Cancer of Prostate
| Article | Year |
|---|---|
Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer.
Topics: Antigens, Nuclear; DNA Breaks, Double-Stranded; DNA End-Joining Repair; DNA Repair; Hepatocyte Nuclear Factor 3-alpha; Humans; Ivermectin; Ku Autoantigen; Male; Prostatic Neoplasms | 2022 |
Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway.
Topics: Androgen Antagonists; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; Humans; Ivermectin; Male; Phenotype; Prostatic Neoplasms; Signal Transduction | 2023 |
Eprinomectin, a novel semi-synthetic macrocylic lactone is cytotoxic to PC3 metastatic prostate cancer cells via inducing apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Cytotoxins; Dose-Response Relationship, Drug; Humans; Ivermectin; Lactones; Macrocyclic Compounds; Male; PC-3 Cells; Prostatic Neoplasms; Reactive Oxygen Species | 2020 |